Page last updated: 2024-11-12

ici 195739

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ICI 195739: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10030147
CHEMBL ID4797953
SCHEMBL ID5439180
MeSH IDM0162470

Synonyms (10)

Synonym
ici 195739
(e)-(+)-2-(2,4-difluorophenyl)-1-{3-[4-(2,2,3,3-tetrafluoropropoxy)styryl]-1h-1,2,4-triazol-1-yl}-3-(1h-1,2,4-triazol-1-yl)propan-2-ol
2-(2,4-difluorophenyl)-1-{3-[(e)-4-(2,2,3,3-tetrafluoropropoxy)styryl]-1h-1,2,4-triazol-1-yl}-3-(1h-1,2,4-triazol-1-yl)propan-2-ol
2-(2,4-difluorophenyl)-1-{3-[(e)-4-(2,2,3,3-tetrafluoropropoxy)styryl]-1h-1,2,4-triazol-1-yl}-3-(1h-1,2,4-triazol-1-yl) propan-2-ol
SCHEMBL5439180
CHEMBL4797953
DTXSID70869909
194798-94-2
2-(2,4-difluorophenyl)-1-(3-{(e)-2-[4-(2,2,3,3-tetrafluoropropoxy)phenyl]vinyl}-1h-1,2,4-triazol-1-yl)-3-(1h-1,2,4-triazol-1-yl)-2-propanol
AKOS040745863

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The terminal plasma half-life of D0870 in plasma following dosing on day 5 ranged from 23 to 85 h (mean, 49 h)."( Pharmacokinetics of two multiple-dosing regimens of D0870 in human immunodeficiency virus-positive patients: a phase I study.
Clumeck, AN; De Wit, S; Edwards, J; O'Doherty, E; Smith, RP; Yates, R, 1998
)
0.3

Bioavailability

ExcerptReferenceRelevance
"We have incorporated several inhibitors of sterol biosynthesis into long-circulating polyethyleneglycol-polylactide (PEG-PLA) nanospheres in order to improve the bioavailability of these poorly soluble compounds."( Cure of experimental Chagas' disease by the bis-triazole DO870 incorporated into 'stealth' polyethyleneglycol-polylactide nanospheres.
Brener, Z; Gref, R; Molina, J; Urbina, J, 2001
)
0.31

Dosage Studied

ExcerptRelevanceReference
" Twenty-two human immunodeficiency virus (HIV)-positive male subjects were enrolled in an open, nonrandomized trial investigating the pharmacokinetics of two different dosing regimens of D0870 and assessing the safety of multiple oral doses of D0870 in HIV-positive subjects and their ability to tolerate multiple oral doses."( Pharmacokinetics of two multiple-dosing regimens of D0870 in human immunodeficiency virus-positive patients: a phase I study.
Clumeck, AN; De Wit, S; Edwards, J; O'Doherty, E; Smith, RP; Yates, R, 1998
)
0.3
" In the present study, we evaluated the influences of epinephrine and isoproterenol on the onset of TdP each time D0870 was given to 6 anesthetized open-chest dogs at a dosage of 20 mg/kg, 5 times every 40 minutes, by the simultaneous measurements of surface electrocardiogram and epicardial monophasic action potential (MAP)."( Influences of catecholamines on the sudden death induced in dogs by an antifungal agent, D0870.
Aldridge, A; Duffy, PA; Harada, T; Matsunaga, T; Mitsui, T; Murano, H; Shibutani, Y, 2000
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (48)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (10.42)18.7374
1990's37 (77.08)18.2507
2000's6 (12.50)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.12 (24.57)
Research Supply Index4.03 (2.92)
Research Growth Index5.14 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (7.84%)5.53%
Reviews4 (7.84%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other43 (84.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]